JERSEY CITY, N.J., June 28,
2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma
America, Inc. (MTPA) today announced three presentations on
investigational ND0612 in Parkinson's disease (PD) will be shared
at the 10th Congress of the European Academy of
Neurology (EAN), being held in Helsinki,
Finland, June 29 –
July 2.
"We are excited to be at EAN this year to showcase our ongoing
research and engage with the scientific community," said
Gustavo A. Suarez Zambrano, M.D.,
Vice President of Medical Affairs, MTPA. "These findings highlight
our dedication to advancing the understanding of investigational
ND0612 and our commitment to recognizing the unmet needs of people
living with Parkinson's disease."
Presentation Details:
Presentations include findings
from subgroup analyses of the pivotal Phase 3 multi-center,
randomized, double-blind double-dummy BouNDless trial (NCT04006210)
evaluating the efficacy, safety and tolerability of investigational
ND0612 in people with PD experiencing motor fluctuations, as well
as a secondary analysis from a Phase 2 study (NCT02577523), which
evaluated the onset of efficacy with ND0612 utilizing patient and
clinical global ratings. Additionally, findings from an analysis
characterizing infusion site reactions in patients who received
24-hour subcutaneous infusion of ND0612 will be shared.
- Subgroup Analyses of a Phase 3, Randomized Study of
Levodopa/Carbidopa Infusion (ND0612) for Parkinson's
Patients (Nelson Lopes,
M.D.; NeuroDerm)
ePresentation Session: "Movement
Disorders 1" (EPR-082): 2:10 p.m. –
2:15 p.m. CEST, June 29
- Onset of Efficacy with Levodopa/Carbidopa Infusion (ND0612)
for Parkinson's Patients (Nelson Lopes, M.D.;
NeuroDerm)
ePresentation Session: "Movement
Disorders 1" (EPR-083): 2:15 p.m. –
2:20 p.m. CEST, June 29
- Characterization of Infusion Site Reactions With 24-hour
Subcutaneous Infusion of ND0612 (Nelson Lopes, M.D.;
NeuroDerm)
ePresentation Session: "Movement
Disorders 1" (EPR-084): 2:20 p.m. –
2:25 p.m. CEST, June 29
About ND0612
ND0612 is an investigational drug-device combination therapy – a
24-hours/day, continuous subcutaneous (SC) infusion of liquid
levodopa/carbidopa (LD/CD) for the treatment of motor fluctuations
in people with Parkinson's disease (PD). Development of
investigational ND0612 is being led by NeuroDerm, Ltd., a
wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation
(MTPC).
About Mitsubishi Tanabe Pharma America, Inc.
Based in Jersey City, N.J.,
Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned
subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). It was
established by MTPC to develop and advance our pipeline as well as
commercialize approved pharmaceutical products in North America. For more information, please
visit www.mt-pharma-america.com or follow us on X (formerly
Twitter), Facebook and LinkedIn.
About Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of
Mitsubishi Chemical Group (MCG), is one of the oldest
pharmaceutical companies in the world, founded in 1678. MTPC is
headquartered in Doshomachi, Osaka, the birthplace of Japan's pharmaceutical industry. MCG has
positioned health care as its strategic focus in its management
policy, "Forging the future". MTPC sets the MISSION of "Creating
hope for all facing illness". To that end, MTPC is working on the
disease areas of central nervous system, immuno-inflammation,
diabetes and kidney, and cancer. MTPC is focusing on "precision
medicine" to provide drugs with high treatment satisfaction and
additionally working to develop "around the pill solutions" to
address specific patient concerns based on therapeutic medicine,
including prevention of diseases, pre-symptomatic disease care,
prevention of aggravation and prognosis. For more information, go
to https://www.mt-pharma.co.jp/e/.
About NeuroDerm, Ltd.
NeuroDerm, Ltd. is a wholly-owned subsidiary of Mitsubishi Tanabe
Pharma Corporation (MTPC), based in Israel, inspired to reduce
disease burden and improve the quality of life of patients and
their families through innovative drug-device combination
therapies and technologies. NeuroDerm is an integrated
pharmaceutical and medical technology company developing central
nervous system (CNS) product candidates. For additional
information, please visit NeuroDerm's
website at www.neuroderm.com or follow the Company
on LinkedIn.
Media inquiries:
Media_MTPA@mt-pharma-us.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-to-present-latest-parkinsons-disease-research-at-the-10th-congress-of-the-european-academy-of-neurology-302184636.html
SOURCE Mitsubishi Tanabe Pharma America